Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging drugs for hepatitis B.

Fabien Zoulim1

  • 1INSERM, U871, 151 cours Albert Thomas, 69424 Lyon cedex 03, France. zoulim@lyon.inserm.fr

Expert Opinion on Emerging Drugs
|July 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Evaluation of the Elecsys HCV Duo Immunoassay for Active Hepatitis C Detection: Insights From the DEPCDUO Study.

Journal of medical virology·2026
Same author

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia.

Gut·2026
Same author

Liver Transplantation for HBV-Related Disease in France: NUC Type Before LT Is Associated With Patient Survival.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Dysregulated transcription in core- and pol-specific CD8 T cells can be targeted by HDAC inhibition to improve T-cell function in chronic hepatitis B.

Journal of hepatology·2026
Same author

B-BEST: Profiling the intrahepatic HBV reservoir at single-cell resolution.

Hepatology (Baltimore, Md.)·2026
Same author

Hepatitis D Virus: Enigmas and Gaps of Knowledge.

Viruses·2026

Chronic hepatitis B treatment faces challenges due to persistent infections and antiviral drug resistance. New therapies, including polymerase inhibitors and combination treatments, are crucial for managing this global health issue.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) remains a significant global health concern, causing cirrhosis and hepatocellular carcinoma.
  • Current nucleoside analog therapies face limitations due to viral persistence and the development of drug resistance.

Purpose of the Study:

  • To highlight the challenges in treating chronic hepatitis B.
  • To emphasize the need for novel antiviral strategies to overcome drug resistance and improve treatment outcomes.

Main Methods:

  • Review of current treatment landscape for chronic hepatitis B.
  • Analysis of mechanisms of antiviral drug resistance.
  • Exploration of potential future therapeutic approaches.

Main Results:

Related Experiment Videos

  • Viral persistence during therapy leads to antiviral drug resistance.
  • Existing treatments are insufficient to eradicate the virus or prevent resistance.
  • New therapeutic agents and strategies are urgently required.

Conclusions:

  • Novel polymerase inhibitors are needed to manage resistance to existing drugs.
  • Combination therapy trials are essential to delay drug resistance.
  • Future strategies should include agents targeting various viral life cycle steps and immune modulators for sustained response.